TNW-BET-AOT

I am a pharmaceutical and entrepreneurial scientist who has a passion to develop engineered therapeutics which are beyond the state-of-the-art therapeutics. My major focus ares are fibrosis and tumor microenvironment. I combine multiple disciplines of peptide chemistry, nanomedicine, molecular biology and bioengineering tools to address challenges of these complex pathologies. 

I have an educational background in Pharmacology and Targeted Drug Delivery. I obtained PhD (cum laude) in 2006 from¬†University of Groningen¬†(The Netherlands) to design drug targeting strategies against kidney fibrosis. I then worked as a Vice President ‚Äď Preclinical Research at BiOrion Technologies with a joint position at the University of Groningen. In 2011, I joined¬†Karolinska Institutet¬†in Stockholm as Forskarassistent (Assistant Professor) by receiving several prestigious grants¬†Swedish Cancer Foundation grant,¬†Marie Curie Career Integration Grant and Swedish Research Council young researcher grant. I set up a team to research on finding new targets in the tumor microenvironment, in particular in cancer-associated fibroblasts (CAFs). Then I¬†was offered a Tenure-Track professor position at University of Twente to set up the new line of tumor microenvironment and targeted therapeutics. In the past years, I have gained unique expertise in finding therapeutic targets in CAFs and immune cells and cell-specific targeting strategies to re-program the tumor microenvironment. I have set up a team to develop 3D bioengineered tumor models to test novel engineered therapeutics. In 2019, I visited School of Engineering and Applied Sciences (SEAS) in¬†Harvard University¬†for a few months and initiated new research collaborations.

Based on my inventions, I have founded a spin-off company ScarTec Therapeutics, which is developing novel peptide therapeutics for the treatment of organ fibrosis and tumor stroma. ScarTec has received NWO Take-off phase-1, phase-2 and H2020 SME phase-1 funding.

It was my honour to serve as the President of Controlled Release Society (CRS) local chapter for BeNeLux and France from 2021-2023. 

In 2024, I was awarded with European Research Council (ERC) Advanced Grant 2023 of 2.5 million for 5 years to lead research on extracellular matrix remodelling to advance immunotherapy against pancreatic cancer. 

Expertise

  • Pharmacology, Toxicology and Pharmaceutical Science

    • Neoplasm
    • Malignant Neoplasm
  • Medicine and Dentistry

    • Combination Therapy
    • Stroma
    • Peptide
    • Cells
  • Biochemistry, Genetics and Molecular Biology

    • Fibroblast
    • Integrin

Organisations

Ancillary activities

  • ScarTec TherapeuticsManagement of ScarTec Therapeutics

The lab is carrying out dynamic inter-disciplinary research in the field of peptide therapeutics, cell-specific targeted delivery and nanomedicine for the indications in the field of fibrotic diseases and (immuno)-oncology. 

In recent years, the significance of¬†fibrosis¬†in¬†solid tumors¬†has been highlighted in driving the tumor progression, invasion¬†and metastasis. The crosstalk between tumor cells and stromal cells such as cancer-associated fibroblasts (CAFs), immune cells such as tumor-associated macrophages (TAMs) as well as extracellular matrix (ECM) is essential to maintain and stimulate the tumor growth and progression. The lab is, on the one hand, uncovering the underlying biology of tumor‚Äďstroma interaction, while on the other hand, developing innovative technologies to target specific tumor stromal cells to develop new therapeutics.¬†

¬†The lab has the following major research themes ‚Äst

  1. Understanding the crosstalk between different cell types within the tumor microenvironment, especially focused on fibroblasts, macrophages and matrix interaction. We have recently investigated the role of several therapeutic targets such as intergrin alpha5 and alpha11 which are involved in these crosstalks. 
  2. Peptide technologies as therapeutics to re-program the tumor microenvironment in order to enhance¬†anti-tumour¬†effect of chemotherapy ‚Äď the lab has recently developed novel peptidomimetic against alpha5¬†which has led to the startup company ScarTec Therapeutics BV.
  3. Targeted nanomedicine to deliver therapeutic molecules (e.g. microRNA delivery, protein and peptide delivery) to specific cells within the tumor microenvironment to treat cancer. 
  4. Nanotheranostic approaches to probe the stromal cells and immune cells within the tumour microenvironment using novel targeting ligands with a goal of personalized medicine.
  5. 3D Bioengineering technologies to emulate the tumor microenvironment (e.g. multicellular tumor spheroids, tumor-on-chip models, 3D bioprinted tumor models). We have developed 3D heterospheroid tumor model to study nanomedicine and recently developed a novel 3D bioprinted mini-brain model.

Key Publications

  1. Kuninty, P. R., Binnemars-Postma K.A., Jarray A., Pednekar, K.P., Heinrich, M.A., Pijffers, H., ten Hoopen, H., Storm, G., van Hoogevest, P., den Otter, W., & Prakash J. (2022) Engineering "tail-flipping" nanoliposomes to alter functionality of alternatively-activated macrophages in tumors: a novel biomimicry approach. Nature Communications.  10.1038/s41467-022-32091-9 (Impact factor: 17.7)
  2. Heinrich MA, Uboldi I, Kuninty PR, Ankone MJK, van Baarlen J, Zhang YS, Jain K, Prakash J. (2022) Microarchitectural mimicking of stroma-induced vasculature compression in pancreatic tumors using a 3D engineered model. Bioactive Materials. 22:18-33 (Impact factor 16.4)
  3. Kuninty, P. R., Bansal, R., S., D. G., Mardhian, D. F., Schnittert, J., van Baarlen, J., Storm, G., Bijlsma, M., van Laarhoven, Metselaar, J. M., Kuppen, P. J. K., Vahrmeijer, A., Ostman, A., Sier, C. F. M. & Prakash, J. (2019) ITGA5 inhibition in pancreatic stellate cells attenuates desmoplasia and potentiates efficacy of chemotherapy in pancreatic cancer. Science Advances 4;5(9):eaax2770. doi: 10.1126/sciadv.aax2770. (Impact factor: 14.5)
  4. Heinrich MA, Bansal R, Lammers T, Zhang YS, Schiffelers RM, Prakash J. (2019) 3D-Bioprinted Mini-Brain: A Glioblastoma Model to Study cellular interactions and therapeutics. Advanced Materials. Apr;31(14):e1806590. (Impact factor: 30.1)
  5. Heinrich MA, Mostafa, AMRH, Morton J, Hawinkels LJAC, Prakash J. Translating complexity and heterogeneity of pancreatic tumor: 3D in vitro to in vivo models. Adv Drug Del Rev. 174:265-2. (Impact factor: 17.8)
  6. Rodrigues, J. , Heinrich, M. A. , Teixeira, L. M. , &¬†Prakash, J. (2020) 3D In Vitro Model (R)evolution: Unveiling Tumor‚ÄďStroma Interactions.¬†Trends in cancer. doi.org/10.1016/j.trecan.2020.10.009¬†(Impact factor: 19.0)
  7. Schnittert J, Bansal R, van Baarlen J, Ostman A, Prakash J. (2019) Integrin alpha11 in pancreatic stellate cells regulates tumor stroma interaction in pancreatic cancer. FASEB J May;33(5):6609-6621. (Impact factor: 5.0)
  8. Mardhian D, Storm G, Mishra DP, Bansal R, Prakash J. (2018) Nano-targeted relaxin impairs fibrosis and improves the efficacy of gemcitabine in vivo. J Control Release. 28;290:1-10 (Impact factor: 11.5)

Publications

2024
2023
Repurposing Tamoxifen for Tumor Microenvironment Priming and Enhanced Tumor-Targeted Drug DeliveryAdvanced Therapeutics, 6(11), Article 2300098. Biancacci, I., De Santis, D., Rama, E., Benderski, K., Momoh, J., Pohlberger, R., Moeckel, D., Kaps, L., Rijcken, C. J. F., Prakash, J., Thewissen, M., Kiessling, F., Shi, Y., Peña, Q., Sofias, A. M., Consolino, L. & Lammers, T.https://doi.org/10.1002/adtp.202300098Repositioning the antihistamine ebastine as an intracellular siRNA delivery enhancerInternational journal of pharmaceutics, 644, Article 123348. Muntean, C., Blondeel, E., Harinck, L., Pednekar, K., Prakash, J., De Wever, O., Chain, J. L., De Smedt, S. C., Remaut, K. & Raemdonck, K.https://doi.org/10.1016/j.ijpharm.2023.123348INTEGRIN BINDING PEPTIDE AND USE OF THE SAME. Prakash, J.Strategies to overcome barriers for cancer (nano)medicines. University of Twente. Priwitaningrum, D. L.https://doi.org/10.3990/1.9789036556163Evaluation of paclitaxel-loaded polymeric nanoparticles in 3D tumor model: impact of tumor stroma on penetration and efficacyDrug delivery and translational research, 13(5), 1470-1483. Priwitaningrum, D. L., Pednekar, K., Gabriël, A. V., Varela-Moreira, A. A., Gac, S. L., Vellekoop, I., Storm, G., Hennink, W. E. & Prakash, J.https://doi.org/10.1007/s13346-023-01310-1NANOTME2023 Abstract Book: 2nd International Conference on NANOMEDICINE meets the TUMOR MICROENVIRONMENT (In preparation). Prakash, J. & ten Hoopen, H. W. M.https://doi.org/10.3990/1.9789036556088Microarchitectural mimicking of stroma-induced vasculature compression in pancreatic tumors using a 3D engineered modelBioactive Materials, 22, 18-33. Heinrich, M. A., Uboldi, I., Kuninty, P. R., Ankone, M. J. K., van Baarlen, J., Zhang, Y. S., Jain, K. & Prakash, J.https://doi.org/10.1016/j.bioactmat.2022.09.015In Vivo Detection of Circulating Cancer-Associated Fibroblasts in Breast Tumor Mouse Xenograft: Impact of Tumor Stroma and ChemotherapyCancers, 15(4), Article 1127. Lu, T., Oomens, L., Terstappen, L. W. M. M. & Prakash, J.https://doi.org/10.3390/cancers15041127Endotoxin contamination alters macrophage-cancer cell interaction and therapeutic efficacy in pre-clinical 3D in vitro modelsBiomaterials Advances, 144, Article 213220. Heinrich, M. A., Heinrich, L., Ankone, M. J. K., Vergauwen, B. & Prakash, J.https://doi.org/10.1016/j.bioadv.2022.213220
2022
Cancer immune therapy using engineered ‚Äõtail-flipping‚Äô nanoliposomes targeting alternatively activated macrophagesNature communications, 13(1), Article 4548. Kuninty, P. R., Binnemars-Postma, K., Jarray, A., Pednekar, K. P., Heinrich, M. A., Pijffers, H. J., ten Hoopen, H., Storm, G., van Hoogevest, P., den Otter, W. K. & Prakash, J.https://doi.org/10.1038/s41467-022-32091-9Cancer-associated fibroblasts: Origin, function, imaging, and therapeutic targetingAdvanced drug delivery reviews, 189, Article 114504. Rimal, R., Desai, P., Daware, R., Hosseinnejad, A., Prakash, J., Lammers, T. & Singh, S.https://doi.org/10.1016/j.addr.2022.114504Managing microenvironments: Time to engineer medicines. University of Twente. Prakash, J.Tissue-adhesive hydrogel for multimodal drug release to immune cells in skinActa biomaterialia, 150, 211-220. Day, N. B., Dalhuisen, R., Loomis, N. E., Adzema, S. G., Prakash, J. & Shields IV, C. W.https://doi.org/10.1016/j.actbio.2022.07.053Mimicking tumor microenvironment by 3D bioprinting: 3D cancer modelingBiofabrication, 14(3), Article 032002. Shukla, P., Yeleswarapu, S., Heinrich, M. A., Prakash, J. & Pati, F.https://doi.org/10.1088/1758-5090/ac6d11Targeting of macrophages and hepatic stellate cells for the treatment of liver diseases. University of Twente. Kurniawan, D. W.https://doi.org/10.3990/1.9789036553445Impact of endotoxins on bioengineered tissues and modelsTrends in biotechnology, 40(5), 532-534. Heinrich, M. A., Mangia, M. & Prakash, J.https://doi.org/10.1016/j.tibtech.2021.12.001Designing novel therapeutic strategies against tumor stroma and fibrosis. University of Twente. Mardhian, D. F.https://doi.org/10.3990/1.9789036553179Src kinase as a potential therapeutic target in non-alcoholic and alcoholic steatohepatitisClinical and translational discovery, 2(1), Article e18. Kurniawan, D. W., Booijink, R. S., Jajoriya, A. K., Dhawan, G., Mishra, D., Oosterhuis, D., Argemi, J., Storm, G., Olinga, P., Bataller, R., Mohanty, S. K., Mishra, D. P., Prakash, J. & Bansal, R.https://doi.org/10.1002/ctd2.18Engineering the tumor microenvironment: Novel 3D in vitro models to study cellular interactions & therapeutics. University of Twente. Heinrich, M. A.https://doi.org/10.3990/1.9789036553162The Tumor Stroma: Biology and Therapeutics. Prakash, J.https://doi.org/10.1201/97810032249213D in vitro Models to Mimic the Tumor MicroenvironmentIn The Tumor Stroma: Biology and Therapeutics. Taylor & Francis. Alexander, M., Huynh, N. T., Zhang, Y. S. & Prakash, J.https://doi.org/10.1201/9781003224921-10

Research profiles

Affiliated study programs

Courses academic year 2023/2024

Courses in the current academic year are added at the moment they are finalised in the Osiris system. Therefore it is possible that the list is not yet complete for the whole academic year.

Courses academic year 2022/2023

Volkskrant Newspaper (Sep 2019): Verzwakte muur om kankercellen biedt chemo een kans

 https://www.volkskrant.nl/cs-bf0bd786

Tubantia Newspaper,¬†¬†¬†‚ÄúUT sets new steps in the treatment of pancreatic cancer‚ÄĚ,¬†¬†https://www.tubantia.nl/regio/ut-zet-flinke-stappen-in-behandeling-alvleesklierkanker~a2caecdc/

In the press

German Media: Rettung bei Pankreaskrebs in Sicht?

https://www.oncologieenpraktijk.nl/nieuws/tu-twente-start-klinisch-onderzoek-alvleesklierkanker/

Medicalxpress:

New medicine may enhance the effect of chemotherapy on pancreatic cancer

https://medicalxpress.com/news/2019-09-medicine-effect-chemotherapy-pancreatic-cancer.html

Pharmacube:

http://www.pharmcube.com/news/article/4319?index=news 

Medical Lifesciences

https://www.news-medical.net/news/20190905/New-drug-may-enhance-efficacy-of-chemotherapy-in-pancreatic-cancer.aspx

News on utwente.nl

New Medication May Enhance the effect of Pancreatic Cancer Chemotherapy https://www.utwente.nl/en/news/2019/9/512858/new-medication-may-enhance-the-effect-of-pancreatic-cancer-chemotherapy

Address

University of Twente

Horst - Zuidhorst (building no. 28), room 246
De Horst 2
7522 LW Enschede
Netherlands

Navigate to location

Organisations

Scan the QR code or
Download vCard